- Home
- SAFT vs OPK Comparison
SAFT vs OPK Comparison
Compare SAFT & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- OPK
- Stock Information
- Founded
- SAFT 1979
- OPK 2007
- Country
- SAFT United States
- OPK United States
- Employees
- SAFT N/A
- OPK N/A
- Industry
- SAFT Property-Casualty Insurers
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- OPK Health Care
- Exchange
- SAFT Nasdaq
- OPK Nasdaq
- Market Cap
- SAFT 1.0B
- OPK 1.0B
- IPO Year
- SAFT N/A
- OPK 1995
- Fundamental
- Price
- SAFT $72.58
- OPK $1.35
- Analyst Decision
- SAFT
- OPK Buy
- Analyst Count
- SAFT 0
- OPK 4
- Target Price
- SAFT N/A
- OPK $2.75
- AVG Volume (30 Days)
- SAFT 98.0K
- OPK 2.0M
- Earning Date
- SAFT 11-04-2025
- OPK 07-31-2025
- Dividend Yield
- SAFT 5.04%
- OPK N/A
- EPS Growth
- SAFT 65.99
- OPK N/A
- EPS
- SAFT 5.73
- OPK N/A
- Revenue
- SAFT $1,199,774,000.00
- OPK $664,029,000.00
- Revenue This Year
- SAFT N/A
- OPK N/A
- Revenue Next Year
- SAFT N/A
- OPK $0.84
- P/E Ratio
- SAFT $12.75
- OPK N/A
- Revenue Growth
- SAFT 16.96
- OPK N/A
- 52 Week Low
- SAFT $68.76
- OPK $1.11
- 52 Week High
- SAFT $90.00
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- SAFT 46.92
- OPK 47.95
- Support Level
- SAFT $71.81
- OPK $1.34
- Resistance Level
- SAFT $74.76
- OPK $1.39
- Average True Range (ATR)
- SAFT 1.30
- OPK 0.04
- MACD
- SAFT -0.09
- OPK -0.00
- Stochastic Oscillator
- SAFT 20.90
- OPK 11.11
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.